Intercept Pharmaceuticals Inc logo

Intercept Pharmaceuticals Inc

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, is developing obeticholic acid (OCA), an agonist of the farnesoid X receptor, which is in Phase III clinical trials for the treatment of primary biliary cirrhosis; OCA that is in Phase IIb clinical trials for treating nonalcoholic steatohepatitis; and OCA that is Phase II clinical trial to treat fibrosing cholestatic hepatitis. The company was incorporated in 2002 and is headquartered in New York, New York.

Latest events on Quartr

Previous Events for Intercept Pharmaceuticals Inc




United States of America

About the company

Investor Relations page

Dig deeper into the fundamentals using Quartr - Investor relations

  • Skip straight to the Q&A session
  • Receive notifications about new events
  • Connect the financial calender on your phone
  • Figure out why the stock is up or down
  • Read the transcripts or scroll the deck
  • Access earnings or press releases
Android play link
App store link
Quartr app screenshot